Tri Locum Partners’s Biogen BIIB Stock Holding History

Tri Locum Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-45,814	Closed	-$11.9M	–	30
2023 Q4	$11.9M	Buy	+45,814	New	+$11.3M	5.42%	8
2022 Q4	–	Sell	-90,551	Closed	-$24.2M	–	76
2022 Q3	$24.2M	Buy	+90,551	New	+$19.2M	6.64%	2

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tri Locum Partners's BIIB Position: Q1 2024 in Review

Tri Locum Partners sold out of Biogen (BIIB) in Q1 2024, closing a stake of 45,814 shares — an estimated $11.9M sold.

Tri Locum Partners first reported a position in BIIB in Q3 2022 and held it in 2 quarters. The position peaked at $24.2M in Q3 2022. 955 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

Tri Locum Partners reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
Tri Locum Partners sold 45,814 Biogen shares in Q1 2024, an estimated $11.9M.
Tri Locum Partners first reported a position in Biogen in Q3 2022 and held it in 2 quarters.
Tri Locum Partners's Biogen position peaked at $24.2M in Q3 2022.
955 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on Tri Locum Partners's 13F filing for Q1 2024, filed 15 May 2024.